RxDoctor Payments Data

Apurv Varia, MD

Gastroenterology · The Woodlands, TXNPI 1578857512

Payments from drug & device makers

$21,663in general payments, 2019–2025

Across 1,032 payments — averaging $20.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$5K
  • Johnson & Johnson$2K
  • Takeda Pharmaceuticals U.S.A., Inc.$2K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$1K
  • QOL Medical, LLC$1K
  • Capsovision, Inc.$912
  • plus $9K from 44 others

What the payments were for

  • Consulting fees$8004%
  • Food & beverage$20,71696%
  • Education$1471%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$21,663 in reported general payments places this provider in the 80th percentile of 1,350 gastroenterology providers in Texas.

See all gastroenterology providers in Texas

Medicare billing

Part B allowed, 2024
$241,012
Medicare patients
684
Services billed
5,632

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LinzessLinaclotide82$81,487
XifaxanRifaximin13$41,505
MovantikNaloxegol Oxalate25$16,048
TrulancePlecanatide15$12,917
ClenpiqSod Picosulf/Mag Ox/Citric Ac70$11,858
Mesalamine17$11,438
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates157$9,510
CholestyramineCholestyramine (With Sugar)41$5,050
Dexlansoprazole DrDexlansoprazole15$4,706
Omeprazole276$4,599
Famotidine311$4,023
PlenvuPeg3350/Sod Sul/Nacl/Kcl/Asb/C27$3,857
Budesonide DrBudesonide26$3,771
Pantoprazole Sodium230$2,965
Ursodiol14$2,811

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess$5,099$81,48782 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan, Trulance, Plenvu$1,449$58,27955 claims
Redhill Biopharma Inc.Movantik$229$16,04825 claims
Ferring Pharmaceuticals Inc.Clenpiq$407$11,85870 claims
Braintree Laboratories, Inc.Suflave$404$2,26118 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,350 gastroenterology providers in Texas.

Other gastroenterology in The Woodlands

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →